The Ministry of Health, Labour and Welfare Japan has approved Kisunla, Eli Lilly’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease, or AD, which includes people with mild cognitive impairment as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- FedEx reports downbeat Q1, Nike vet returns as new CEO: Morning Buzz
- Deutsche says Novo data removes competitive threat for Eli Lilly
- Novo Nordisk data for monlunabant ‘negative,’ says BofA
- Novo Nordisk, Eli Lilly offer discounts for insurance coverage, WSJ says
- FDA Approval of EBGLYSS Boosts Eli Lilly’s (NYSE:LLY) Eczema Treatment Portfolio